Canaccord raises Pulse Biosciences stock price target on tech potential

Canaccord has raised its price target on Pulse Biosciences (NASDAQ: PLSE) stock to $58, from the previous $43 level, while maintaining a Buy rating on the stock. The firm recently hosted a virtual non-deal roadshow with Pulse's CEO, Paul LaViolette, and CFO, Jon Skinner, to discuss the company's advancements in nanosecond pulse field ablation technology.

Pulse Biosciences' stock has shown impressive momentum since its initiation by Canaccord on June 4, 2026, rising 87.5% so far. Over the past year, the stock has delivered a remarkable 160% return, and a whopping 268% gain year-to-date, according to InvestingPro data. The company's market capitalization currently stands at $3.6 billion, though Analysts' analysis suggests the stock may be overvalued at its current price.

During the recent roadshow, Canaccord addressed Pulse's nanosecond pulse field ablation platform, clinical evidence, potential use cases, and commercial strategy across its franchises. A key focus was Pulse's atrial fibrillation catheter, nPulse, and its upcoming pivotal trial enrollment completion. Pulse's management believes that a partnership with catheter ablation for nPulse is the most sensible approach for all stakeholders.

The company emphasizes that its disruptive electrophysiology and pulse field ablation technology have a significant market capitalization driver. Canaccord now uses a mid-cap comparison group instead of the previous small-cap group, as Pulse's market capitalization has risen since the last price target update. Their underlying estimates have remained unchanged. Investors can access a Pro Research Report for a more in-depth look at Pulse Biosciences' valuation and growth prospects.

Other recent developments include an equity distribution agreement with Mizuho Securities USA LLC, enabling Pulse Biosciences to sell up to $85 million of its common stock. Several analyst firms, such as BTIG, Freedom Capital, and Needham, have initiated coverage of Pulse Biosciences with positive ratings and target prices ranging from $58 to $73. Canaccord also revised its price target for Pulse Biosciences from $32 to $43, citing clinical and regulatory progress.